[{"orgOrder":0,"company":"Magnet Biomedicine","sponsor":"Newpath Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery Platform","graph3":"Magnet Biomedicine","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Magnet Biomedicine \/ Newpath Partners","highestDevelopmentStatusID":"3","companyTruncated":"Magnet Biomedicine \/ Newpath Partners"}]

Find Clinical Drug Pipeline Developments & Deals by Magnet Biomedicine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : The financing will support Magnet's approach to the discovery and development of TrueGlues™, compounds inducing cooperative protein-protein interactions and will advance its portfolio spanning several indications, including oncology, cardiovascular, an...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 19, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Discovery Platform

                          Sponsor : Newpath Partners

                          Deal Size : $50.0 million

                          Deal Type : Series A Financing

                          blank